External analyst notes, journalism, and industry commentary cited with attribution.
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Cohealyx's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Cohealyx. Showing past 6 months and next 12 months · 2 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Cohealyx | AVITA Medical | Wound Care Biologic | Phase 2[ TODO: fill in ] | Open-label, multi-centre, single-arm trial (per ClinicalTrials.gov NCT06787690). | [ TODO: fill in — not disclosed in available trial registry data ] | [ TODO: fill in ] | 41 patients (per ClinicalTrials.gov NCT06787690) | 41 |
| Microsurfaced Grafts in Deep Burn Wounds |
Read-across commentary attached per trial. Phase ordering preserved within each group.
| Mechanism | Speed to patient | Manufacturing | Best approved result | Durability | Moat |
|---|---|---|---|---|---|
| Mesenchymal Stem CellAllo MSC | Off-the-shelf | Batch (donor) | Ryoncil (GvHD only) | Transient | Low |
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
Phase 4 |
| — |
| — |
| — |
| — |
| — |
| Bioinductive Patch for Full-Thickness Rotator Cuff Tears | Henry Ford Health System | — | Phase 4 | — | — | — | — | — |
| Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting | XenoTherapeutics, Inc. | — | Phase 3 | — | — | — | — | — |
| Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | CUTISS AG | — | Phase 3 | — | — | — | — | — |
| Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | CUTISS AG | — | Phase 2 | — | — | — | — | — |
| Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children | CUTISS AG | — | Phase 2 | — | — | — | — | — |
| Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children | CUTISS AG | — | Phase 2 | — | — | — | — | — |
| Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction | Vanderbilt University Medical Center | — | Phase 2 | — | — | — | — | — |
| EB-OC for the Treatment of Focal Chondral/Osteochondral Defects in the Knee | Epibone, Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |